Publicacións en colaboración con investigadores/as de University of Antwerp (9)

2020

  1. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)

    Critical Reviews in Oncology/Hematology, Vol. 151

  2. Corrigendum to “Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)” [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978] (Critical Reviews in Oncology / Hematology (2020) 151, (S1040842820301165), (10.1016/j.critrevonc.2020.102978))

    Critical Reviews in Oncology/Hematology

2019

  1. The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity

    Carcinogenesis, Vol. 40, Núm. 2, pp. 324-334

2015

  1. Corrigendum to "Liquid biopsies in lung cancer: The new ambrosia of researchers" [Biochem. Biophys. Act. 1846(2014) 539-546]

    Biochimica et Biophysica Acta - Reviews on Cancer

  2. Looking into the "Garden of the Hesperides": New drugs for hepatocellular carcinoma

    Minerva Chirurgica, Vol. 70, Núm. 2, pp. 119-129

  3. Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice

    Clinical and Experimental Metastasis, Vol. 32, Núm. 7, pp. 677-687

  4. cMET in NSCLC: Can we cut off the head of the Hydra? From the pathway to the resistance

    Cancers, Vol. 7, Núm. 2, pp. 556-573

2014

  1. Liquid biopsies in lung cancer: The new ambrosia of researchers

    Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1846, Núm. 2, pp. 539-546

  2. The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target?

    Current Drug Targets, Vol. 15, Núm. 14, pp. 1284-1292